Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5978880 | 0.91 | ALDH1A1 (0.38) | KMT2ALMNAALDH1A1RAB9AKDM4E | |
| Bromide SCHEMBL8081586 | 0.88 | KMT2A (0.54) | KMT2ALMNAALDH1A1RAB9AL3MBTL1 | |
| Bromide SCHEMBL3843812 | 0.88 | KMT2A (0.54) | KMT2ALMNAALDH1A1RAB9AL3MBTL1 | |
| Bromide SCHEMBL7050720 | 0.87 | ALDH1A1 (0.36) | KMT2ALMNAALDH1A1RAB9AKDM4E | |
| Bromide SCHEMBL8081579 | 0.87 | KMT2A (0.53) | KMT2ALMNAALDH1A1RAB9AL3MBTL1 | |
| Bromide SCHEMBL8081581 | 0.87 | KMT2A (0.53) | KMT2ALMNAALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL5071271 | 0.87 | KMT2A (0.52) | KMT2ALMNAALDH1A1RAB9AL3MBTL1 | |
| Bromide SCHEMBL3846115 | 0.83 | LMNA (0.54) | KMT2ALMNAALDH1A1RAB9AHSD17B10 | |
| Hydrochloric Acid SCHEMBL5069533 | 0.83 | LMNA (0.50) | KMT2ALMNAALDH1A1RAB9AHSD17B10 | |
| Hydrochloric Acid SCHEMBL5071101 | 0.83 | LMNA (0.50) | KMT2ALMNAALDH1A1RAB9AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384625-B2 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARINGTON PHARMACEUTICALS, LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-6713050-B2 | A THIAZOLIUM COMPOUND FOR TREATMENT OF HAIR, NAIL, EX-VIVO ORGAN, TISSUE OR CELLS BY IMPROVING THE DEFORMABILITY AND DIFFUSION COEFFICIENT OF HAIR, NAILS, TISSUES, CELLS, AND ORGANS IN HUMAN AND ANIMALS | FARRINGTON PHARMACEUTICALS, INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030185776-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARRINGTON PHARMACEUTICALS, LLC | 2003-10-02 | — | — | US | disclosed |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-05 | — | — | US | disclosed |
| WO-2002056836-A2 | METHOD AND COMPOSITION FOR REJUVENATING HAIR, NAILS, TISSUES, CELLS AND ORGANS BY EX-VIVO OR IMMERSIVE TREATMENT | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185776-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | COL1A1, KRT18, MMP1 | KMT2A 2650/4885LMNA 216/4885ALDH1A1 1168/4885 |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | COL1A1, KRT18, COL2A1 | KMT2A 2711/4885LMNA 232/4885ALDH1A1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.